Alterna Therapeutics is a biotechnology company developing a library of first-in-class small molecules targeting the SHIP enzyme.
In obesity, SHIP inhibition promotes the survival of immunoregulatory cell types in fat tissue that are known to limit inflammation, and thus can reverse obesity and normalize blood sugar control. Alterna’s lead compounds have shown efficacy in multiple animal models of obesity and diabetes.
In blood cell disorders, SHIP inhibition serves to mobilize and expand hematopoietic and mesenchymal stem cell populations and increase endogenous production of key blood cell growth factors; thus, it can promote more rapid recovery of all blood cell populations. Alterna is exploring its lead compounds in the areas of bone marrow transplant and post-myeloablative therapy.
In cancer, SHIP inhibition has shown promising effects in multiple indications, including: myeloma, breast cancer, and colon cancer. Additionally, SHIP inhibition can boost immune responses to cancer, giving Alterna’s lead compounds potential in immuno-oncology.
Alterna Therapeutics is based on technology licensed from SUNY Upstate Medical University and Syracuse University, developed primarily by Dr. William G. Kerr, Professor of Microbiology and Immunology and Pediatrics at SUNY Upstate Medical.